GSK Sets Sights on £40bn Revenue Ambition as ShoreCap Raises Target to 2,500p

Shore Capital believes GSK has achieved its medium-term plan a year ahead of schedule, making a £40 billion revenue ambition for 2031 credible. The broker argues that hitting the plan early shifts the debate around credibility and long-term value. HIV is seen as a "glidepath, not a cliff," and Specialty Medicines is expected to drive growth. Shore forecasts 15% constant currency growth in FY26, up from the company's guidance of low double-digit growth. The broker also raises its 2031 revenue forecast to £40 billion from £38 billion, citing pipeline progress across various disease areas.